OBJECTIVE: To assess the balance between costs and effects of the sirolimus eluting stent in the treatment of single native de novo coronary lesions in the RAVEL (randomised study with the sirolimus eluting Bx Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions) study. DESIGN: Multicentre, double blind, randomised trial. SETTING:Percutaneous coronary intervention for single de novo coronary lesions. PATIENTS: 238 patients with stable or unstable angina. INTERVENTIONS: Randomisation to sirolimus eluting stent or bare stent implantation. MAIN OUTCOME MEASURES: Patients were followed up to one year and the treatment effects were expressed as one year survival free of major adverse cardiac events (MACE). Costs were estimated as the product of resource utilisation and Dutch unit costs. RESULTS: At one year, the absolute difference in MACE-free survival was 23% in favour of the sirolimus eluting stent group. At the index procedure, sirolimus eluting stent implantation had an estimated additional procedural cost of 1286. At one year, however, the estimated additional cost difference had decreased to 54 because of the reduction in the need for repeat revascularisations in the sirolimus group (0.8% v 23.6%; p < 0.01). After adjustment of actual results for the consequences of angiographic follow up (correction based on data from the BENESTENT (Belgium Netherlands stent) II study), the difference in MACE-free survival was estimated at 11.1% and the additional one year costs at 166. CONCLUSIONS: The one year data from RAVEL suggest an attractive balance between costs and effects for sirolimus eluting stents in the treatment of single native de novo coronary lesions. The cost effectiveness of drug eluting stents in more complex lesion subsets remains to be determined.
RCT Entities:
OBJECTIVE: To assess the balance between costs and effects of the sirolimus eluting stent in the treatment of single native de novo coronary lesions in the RAVEL (randomised study with the sirolimus eluting Bx Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions) study. DESIGN: Multicentre, double blind, randomised trial. SETTING: Percutaneous coronary intervention for single de novo coronary lesions. PATIENTS: 238 patients with stable or unstable angina. INTERVENTIONS: Randomisation to sirolimus eluting stent or bare stent implantation. MAIN OUTCOME MEASURES: Patients were followed up to one year and the treatment effects were expressed as one year survival free of major adverse cardiac events (MACE). Costs were estimated as the product of resource utilisation and Dutch unit costs. RESULTS: At one year, the absolute difference in MACE-free survival was 23% in favour of the sirolimus eluting stent group. At the index procedure, sirolimus eluting stent implantation had an estimated additional procedural cost of 1286. At one year, however, the estimated additional cost difference had decreased to 54 because of the reduction in the need for repeat revascularisations in the sirolimus group (0.8% v 23.6%; p < 0.01). After adjustment of actual results for the consequences of angiographic follow up (correction based on data from the BENESTENT (Belgium Netherlands stent) II study), the difference in MACE-free survival was estimated at 11.1% and the additional one year costs at 166. CONCLUSIONS: The one year data from RAVEL suggest an attractive balance between costs and effects for sirolimus eluting stents in the treatment of single native de novo coronary lesions. The cost effectiveness of drug eluting stents in more complex lesion subsets remains to be determined.
Authors: M van den Brand; C van Halem; F van den Brink; P de Feyter; P Serruys; H Suryapranata; K Meeter; E Bos; F J van Dalen Journal: Eur Heart J Date: 1990-08 Impact factor: 29.983
Authors: P W Serruys; F Unger; J E Sousa; A Jatene; H J Bonnier; J P Schönberger; N Buller; R Bonser; M J van den Brand; L A van Herwerden; M A Morel; B A van Hout Journal: N Engl J Med Date: 2001-04-12 Impact factor: 91.245
Authors: P N Ruygrok; R Melkert; M A Morel; J A Ormiston; F W Bär; F Fernandez-Avilès; H Suryapranata; K D Dawkins; C Hanet; P W Serruys Journal: J Am Coll Cardiol Date: 1999-11-01 Impact factor: 24.094
Authors: P W Serruys; B de Bruyne; S Carlier; J E Sousa; J Piek; T Muramatsu; C Vrints; P Probst; R Seabra-Gomes; I Simpson; V Voudris; O Gurné; N Pijls; J Belardi; G A van Es; E Boersma; M A Morel; B van Hout Journal: Circulation Date: 2000-12-12 Impact factor: 29.690
Authors: P W Serruys; B van Hout; H Bonnier; V Legrand; E Garcia; C Macaya; E Sousa; W van der Giessen; A Colombo; R Seabra-Gomes; F Kiemeneij; P Ruygrok; J Ormiston; H Emanuelsson; J Fajadet; M Haude; S Klugmann; M A Morel Journal: Lancet Date: 1998-08-29 Impact factor: 79.321
Authors: Joachim Schofer; Michael Schlüter; Anthony H Gershlick; William Wijns; Eulogio Garcia; Erick Schampaert; Günter Breithardt Journal: Lancet Date: 2003-10-04 Impact factor: 79.321
Authors: Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245